diff --git a/.DS_Store b/.DS_Store index 6700d88..08aa7b2 100644 Binary files a/.DS_Store and b/.DS_Store differ diff --git a/public/.DS_Store b/public/.DS_Store new file mode 100644 index 0000000..e033773 Binary files /dev/null and b/public/.DS_Store differ diff --git a/views/.DS_Store b/views/.DS_Store index 61cbec6..9dee767 100644 Binary files a/views/.DS_Store and b/views/.DS_Store differ diff --git a/views/components/sidebar.html b/views/components/sidebar.html deleted file mode 100644 index e69de29..0000000 diff --git a/views/pages/.DS_Store b/views/pages/.DS_Store index d39dd89..5277914 100644 Binary files a/views/pages/.DS_Store and b/views/pages/.DS_Store differ diff --git a/views/pages/patient/.DS_Store b/views/pages/patient/.DS_Store index 2fa4683..288ec0d 100644 Binary files a/views/pages/patient/.DS_Store and b/views/pages/patient/.DS_Store differ diff --git a/views/pages/patient/appointments.html b/views/pages/patient/appointments.html index e7dbcfa..bdfa118 100644 --- a/views/pages/patient/appointments.html +++ b/views/pages/patient/appointments.html @@ -193,39 +193,49 @@
- -
-
- -
-
John Doe
- Patient -
-
-
- - Dashboard - - - Appointments - - - Reports - - - Care Plan - - - Resources - - - Profile - - - Feedback - -
-
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+
diff --git a/views/pages/patient/cancer-conditions.html b/views/pages/patient/cancer-conditions.html new file mode 100644 index 0000000..9e66b47 --- /dev/null +++ b/views/pages/patient/cancer-conditions.html @@ -0,0 +1,552 @@ + + + + + + MedConnect - Cancer Conditions + + + + + + + +
+
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ + +
+
+

Cancer Conditions

+ +
+ + +
+ + + + + + + + +
+ + +
+ +
+
+
Primary Condition: Breast Cancer
+ Primary +
+
+
+
Condition Code
+
254837009
+
+
+
Display Name
+
Malignant neoplasm of breast
+
+
+
Body Site
+
Breast
+
+
+
Histology/Morphology
+
Invasive ductal carcinoma
+
+
+
Laterality
+
Right
+
+
+
TNM Stage Group
+
Stage IIA
+
+
+ Diagnosed: June 15, 2023 + Under Treatment +
+
+
+
+ + +
+
+
+
+ + + +
+
+
+ + + + +
+ + + + + + + \ No newline at end of file diff --git a/views/pages/patient/dashboard.html b/views/pages/patient/dashboard.html index 6d7c26a..041b0b7 100644 --- a/views/pages/patient/dashboard.html +++ b/views/pages/patient/dashboard.html @@ -132,38 +132,50 @@
-
-
- -
-
John Doe
- Patient -
-
-
- - Dashboard - - - Appointments - - - Reports - - - Care Plan - - - Resources - - - Profile - - - Feedback - -
-
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ +
@@ -376,9 +388,11 @@
Recovery & Follow-up
- + + + \ No newline at end of file diff --git a/views/pages/patient/disease-status.html b/views/pages/patient/disease-status.html new file mode 100644 index 0000000..abd5c35 --- /dev/null +++ b/views/pages/patient/disease-status.html @@ -0,0 +1,535 @@ + + + + + + MedConnect - Disease Status + + + + + + + +
+
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ + +
+
+

Disease Status

+ +
+ + +
+
+
Current Disease Status
+
+
+
+
+
+
Status
+
+ + Remission + + Updated: Apr 10, 2025 +
+
+ +
+
Primary Cancer
+

Invasive Ductal Carcinoma, Breast

+

Diagnosed: Jan 15, 2024

+
+
+ +
+
Status Timeline
+
+
+
+

Apr 10, 2025 - Remission

+

Post-treatment evaluation

+
+
+
+

Feb 20, 2025 - Responding

+

Mid-treatment assessment

+
+
+
+

Jan 15, 2024 - Active

+

Initial diagnosis

+
+
+
+
+
+
+ + +
+
+
Evidence Supporting Current Status
+
+
+
+
+ +
+
Pathology Report
+ Apr 5, 2025 +
+
+

No evidence of residual invasive carcinoma or ductal carcinoma in situ (DCIS). Complete pathological response to neoadjuvant therapy.

+
+ View full report +
+
+ +
+
+ +
+
Imaging Study (MRI)
+ Apr 2, 2025 +
+
+

No evidence of residual tumor. Post-surgical changes noted. No suspicious enhancement.

+
+ View full report +
+
+ +
+
+ +
+
Tumor Marker Test
+ Apr 3, 2025 +
+
+

CA 15-3: 15 U/mL (Within normal range: 0-30 U/mL)

+
+ View test details +
+
+
+
+ + +
+
+
All Cancer Conditions Status
+
+
+
+ + + + + + + + + + + + + + + + + + + + + + +
Cancer TypeLocationCurrent StatusLast UpdatedActions
Invasive Ductal CarcinomaBreast, Right +
+ + Remission +
+ 		Apr 10, 2025 +
+ + +
+
No other cancer conditions recorded
+
+
+
+ + +
+
+
+
+
Treatment Response
+
+
+
+
Current Treatment Protocol
+

Completed AC-T Regimen (Adriamycin, Cyclophosphamide, Taxol)

+

Jan 2024 - Mar 2025

+
+ +
+
Response Assessment
+
+
+ Tumor Size Reduction + 100% +
+
+
+
+
+ +
+ +
+
Complete Response (CR)
+

No detectable evidence of disease after completion of treatment

+
+
+
+
+
+
+ +
+
+
+
Next Steps
+
+
+
+
+
+
+
25
+ MAY +
+
+
+
Follow-up with Dr. Smith
+

3-month post-treatment assessment

+
+
+
+ +
+
Maintenance Therapy
+

Hormone Therapy: Tamoxifen

+

Started: Apr 15, 2025 | Duration: 5 years

+
+ +
+ +
+
Regular Monitoring Schedule
+

Clinical examination every 3 months, imaging studies every 6 months for first 2 years

+
+
+
+
+ + View Complete Care Plan + +
+
+
+
+
+
+
+ + + + +
+ + + + + + \ No newline at end of file diff --git a/views/pages/patient/feedback.html b/views/pages/patient/feedback.html deleted file mode 100644 index e69de29..0000000 diff --git a/views/pages/patient/profile.html b/views/pages/patient/profile.html index 38bf7ce..7d30b19 100644 --- a/views/pages/patient/profile.html +++ b/views/pages/patient/profile.html @@ -203,38 +203,49 @@
-
-
- -
-
John Doe
- Patient -
-
-
- - Dashboard - - - Appointments - - - Reports - - - Care Plan - - - Resources - - - Profile - - - Feedback - -
-
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+
diff --git a/views/pages/patient/reports.html b/views/pages/patient/reports.html index ec20f57..b8acff5 100644 --- a/views/pages/patient/reports.html +++ b/views/pages/patient/reports.html @@ -248,40 +248,49 @@
- -
-
- -
-
John Doe
- Patient -
-
-
- - Dashboard - - - Appointments - - - Reports - - - Care Plan - - - Resources - - - Profile - - - Feedback - -
-
- + +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+
diff --git a/views/pages/patient/resources.html b/views/pages/patient/resources.html deleted file mode 100644 index e69de29..0000000 diff --git a/views/pages/patient/risk-assessments.html b/views/pages/patient/risk-assessments.html new file mode 100644 index 0000000..91c7985 --- /dev/null +++ b/views/pages/patient/risk-assessments.html @@ -0,0 +1,786 @@ + + + + + + MedConnect - Risk Assessments + + + + + + + +
+
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ + +
+

Risk Assessments

+ + + + + + + +
+ +
+
+ +
+
+
+
Risk Summary
+
+
+
+ 2 +
+

Intermediate Risk

+

Last assessed: Mar 15, 2025

+
+
+ Current Risk Level: + Intermediate +
+
+ Risk Trend: + Improving +
+
+
+
+ + +
+
+
+
Rhabdomyosarcoma Risk Factors
+
+
+
+
+
Histologic Type
+ Based on pathology report +
+
+ Embryonal +
+
+ +
+
+
Primary Site
+ Location impact on risk +
+
+ Favorable +
+
+ +
+
+
Tumor Size
+ From imaging studies +
+
+ 5-10 cm +
+
+ +
+
+
Regional Lymph Node Involvement
+ Status of nearby lymph nodes +
+
+ N1 +
+
+ +
+
+
Distant Metastasis
+ Spread to distant organs +
+
+ Not Detected +
+
+
+
+ +
+
+
+ + +
+
+
+
Risk Assessment History
+
+
+
+
+
+
15
+ MAR +
+
+
+
Intermediate Risk (Group 2)
+
Assessed by Dr. Smith
+
+
+
+
+
+ +
+
+
+
02
+ FEB +
+
+
+
High Risk (Group 3)
+
Assessed by Dr. Johnson
+
+
+
+
+
+ +
+
+
+
10
+ JAN +
+
+
+
High Risk (Group 3)
+
Initial Assessment by Dr. Smith
+
+
+
+
+
+
+
+
+ + +
+
+
+
Clinical Recommendations
+
+
+
+
+ +
+
Risk-Adapted Treatment Plan
+

Based on your intermediate risk assessment, a combination approach of surgery, chemotherapy, and radiation therapy is recommended.

+
+
+
+ +
+ +
+
Follow-up Schedule
+

Monthly follow-ups for the first year, with imaging studies every 3 months to monitor response to treatment.

+
+
+ +
+ +
+
Clinical Trial Eligibility
+

You may be eligible for the ARST2023 clinical trial for intermediate-risk rhabdomyosarcoma. Discuss with your oncologist at your next appointment.

+
+
+
+
+
+
+
+ + +
+
+ +
+
+
+
Risk Summary
+
+
+
+ 1 +
+

Standard Risk

+

Last assessed: Mar 10, 2025

+
+
+ Current Risk Level: + Standard +
+
+ Risk Trend: + Stable +
+
+
+
+ + +
+
+
+
ALL Risk Factors
+
+
+
+
+
Age
+ Impact on risk classification +
+
+ 1-9 years +
+
+ +
+
+
Initial White Blood Cell Count
+ At diagnosis +
+
+ < 50,000/µL +
+
+ +
+
+
Cytogenetics
+ Chromosome analysis +
+
+ Favorable +
+
+ +
+
+
CNS Involvement
+ Central nervous system status +
+
+ CNS-1 +
+
+ +
+
+
Minimal Residual Disease
+ Day 29 assessment +
+
+ < 0.01% +
+
+
+
+ +
+
+
+ + +
+
+
+
Risk Assessment History
+
+
+
+
+
+
10
+ MAR +
+
+
+
Standard Risk
+
Assessed by Dr. Wilson
+
+
+
+
+
+ +
+
+
+
05
+ FEB +
+
+
+
Standard Risk
+
Assessed by Dr. Wilson
+
+
+
+
+
+ +
+
+
+
15
+ JAN +
+
+
+
Standard Risk
+
Initial Assessment by Dr. Wilson
+
+
+
+
+
+
+
+
+ + +
+
+
+
Clinical Recommendations
+
+
+
+
+ +
+
Standard-Risk Treatment Protocol
+

Based on your standard risk assessment, a standard three-phase treatment protocol is recommended: Induction, Consolidation, and Maintenance.

+
+
+
+ +
+ +
+
Follow-up Schedule
+

Monthly bone marrow evaluations during induction, followed by quarterly evaluations during maintenance therapy.

+
+
+ +
+ +
+
Supportive Care
+

Standard supportive care measures include infection prevention, nutritional support, and psychosocial services.

+
+
+
+
+
+
+
+
+
+
+
+ + + + + + + +
+ + + + + + + \ No newline at end of file diff --git a/views/pages/patient/sidebar.html b/views/pages/patient/sidebar.html new file mode 100644 index 0000000..6b05f04 --- /dev/null +++ b/views/pages/patient/sidebar.html @@ -0,0 +1,43 @@ + +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ \ No newline at end of file diff --git a/views/pages/patient/test-results.html b/views/pages/patient/test-results.html new file mode 100644 index 0000000..17e73fe --- /dev/null +++ b/views/pages/patient/test-results.html @@ -0,0 +1,933 @@ + + + + + + MedConnect - Test Results + + + + + + + +
+
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ + +
+
+

Test Results

+
+ + +
+
+ + + + +
+ +
+ +
+
+
+
+
Total Tests
+
+

8

+ +
+ Latest: Mar 15, 2025 +
+
+
+
+
+
+
Abnormal Results
+
+

2

+ +
+ Review with your doctor +
+
+
+
+
+
+
Improving Trends
+
+

3

+ +
+ Positive progress indicators +
+
+
+
+ + +
+
+
+
Tumor Marker Trends
+
+ + + CA-125 + + + + CEA + + + + PSA + +
+
+
+
+
+ +
+

+ + Tumor marker trends visualization would be rendered here.
+ This would show changes over time for various markers. +

+
+
+
+
+ +
+
Analysis Insight
+

CA-125 levels show a declining trend since treatment began, indicating positive response to therapy. CEA remains slightly elevated but stable.

+
+
+
+
+
+ + +
+
+
+
Recent Tumor Marker Tests
+
+ +
+
+
+
+
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
DateTestResultReference RangeTrendActions
Mar 15, 2025 +
CA-125
+ Ovarian Cancer + 		+ 28 U/mL + 0-35 U/mL + 18% + + + +
Feb 20, 2025 +
CEA
+ Colon Cancer + 		+ 6.2 ng/mL + 0-5.0 ng/mL + 0.5% + + + +
Feb 20, 2025 +
PSA
+ Prostate Cancer + 		+ 1.8 ng/mL + 0-4.0 ng/mL + 12% + + + +
Jan 05, 2025 +
AFP
+ Liver Cancer + 		+ 12 ng/mL + 0-10 ng/mL + 25% + + + +
Jan 05, 2025 +
CA 15-3
+ Breast Cancer + 		+ 22 U/mL + 0-30 U/mL + 2% + + + +
+
+
+
+ +
+
+
+ + +
+
+
+
+
+
Total Imaging Studies
+
+

5

+ +
+ Latest: Mar 10, 2025 +
+
+
+
+
+
+
Next Scheduled Imaging
+
+
+
+
15
+ APR +
+
+
+
MRI Follow-up
+
2:30 PM
+
Radiology Department, Floor 2
+
+
+
+
+
+
+ + + +
+
+
+
+
Imaging Results Timeline
+
+
+
+
+
MRI Brain with Contrast
+ Mar 10, 2025 +
+

No evidence of metastatic disease in the brain. Previous lesion in left temporal lobe shows 40% reduction in size.

+
+ + +
+
+ +
+
+
CT Chest/Abdomen/Pelvis
+ Feb 05, 2025 +
+

Partial response to treatment. Primary mass shows 30% reduction in size compared to previous imaging. No new lesions identified.

+
+ + +
+
+ +
+
+
PET/CT Whole Body
+ Jan 12, 2025 +
+

Metabolically active disease in primary site and known metastatic sites. No new FDG-avid lesions compared to baseline.

+
+ + +
+
+ +
+
+
MRI Brain with Contrast
+ Dec 18, 2024 +
+

1.5 cm enhancing lesion in left temporal lobe concerning for metastatic disease. Recommended follow-up in 8-10 weeks.

+
+ + +
+
+ +
+
+
CT Chest/Abdomen/Pelvis with Contrast
+ Nov 30, 2024 +
+

Initial staging scan. Primary mass measuring 4.3 x 3.8 cm with evidence of lymph node involvement and two hepatic lesions concerning for metastases.

+
+ + +
+
+
+
+
+
+
+ + +
+ + +
+
+
Complete Blood Count (CBC)
+
+
+
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Test ComponentResultReference RangePreviousChange
White Blood Cell Count3.2 x10^9/L4.0 - 11.0 x10^9/L4.0 - 11.0 x10^9/L3.5 x10^9/L8.6%
Hemoglobin10.2 g/dL13.5 - 17.5 g/dL11.0 g/dL7.3%
Platelet Count180 x10^9/L150 - 450 x10^9/L165 x10^9/L9.1%
Neutrophils1.2 x10^9/L2.0 - 7.5 x10^9/L1.5 x10^9/L20%
Lymphocytes1.5 x10^9/L1.0 - 4.8 x10^9/L1.6 x10^9/L6.3%
+
+
+
+ +
+
Clinical Notes
+

Low white blood cell count and neutrophils may be due to recent chemotherapy. Monitor for signs of infection and fever. Consider growth factor support if counts continue to decrease.

+
+
+
+
+
+ +
+
+
Comprehensive Metabolic Panel (CMP)
+
+
+
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Test ComponentResultReference RangePreviousChange
Glucose125 mg/dL70 - 99 mg/dL118 mg/dL5.9%
BUN15 mg/dL7 - 20 mg/dL14 mg/dL7.1%
Creatinine0.9 mg/dL0.6 - 1.2 mg/dL0.85 mg/dL5.9%
ALT85 U/L7 - 55 U/L72 U/L18.1%
AST65 U/L8 - 48 U/L58 U/L12.1%
+
+
+
+ +
+
Clinical Notes
+

Liver function tests show mild elevation. This may be due to medication effects or liver involvement. Monitor closely and consider dose adjustments if values continue to rise.

+
+
+
+
+
+
+ + +
+
+
+
+
+
Histologic Grade
+
+
+
+
+
+ G2 +
+
+
+
Moderately Differentiated
+

Tumor cells show moderate differentiation with some preserved tissue architecture.

+
+
+
+
Histologic Characteristics:
+
    +
  • Moderate nuclear pleomorphism
    • +
  • Increased mitotic activity (8-10/HPF)
    • +
  • Focal areas of necrosis
    • +
  • Moderate stromal invasion
    • +
+
+
+
+
+
+
+
+
Immunohistochemistry
+
+
+
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
MarkerResultInterpretation
Ki-6725%Moderate proliferation index
p53PositiveAbnormal expression
CD31PositiveVascular invasion present
PD-L15%Low expression
+
+
+
+
+
+ +
+
+
Biopsy Timeline
+
+
+
+
+
Liver Biopsy (Guided by CT)
+ Mar 02, 2025 +
+

Metastatic adenocarcinoma, consistent with known primary. Tumor cells show moderate response to treatment with areas of necrosis and fibrosis.

+
+ + +
+
+ +
+
+
Primary Tumor Re-biopsy
+ Jan 25, 2025 +
+

Adenocarcinoma with moderate differentiation (Grade 2). Tumor showing evolving response to treatment with 40% viable tumor cells.

+
+ + +
+
+ +
+
+
Initial Diagnostic Biopsy
+ Nov 15, 2024 +
+

Adenocarcinoma with moderate to poor differentiation (Grade 2-3). Immunohistochemistry profile consistent with primary gastric origin.

+
+ + +
+
+
+
+
+
+
+
+
+ +
+ + + + + + + \ No newline at end of file diff --git a/views/pages/patient/tnm-staging.html b/views/pages/patient/tnm-staging.html new file mode 100644 index 0000000..42ba3a5 --- /dev/null +++ b/views/pages/patient/tnm-staging.html @@ -0,0 +1,822 @@ + + + + + + MedConnect - TNM Staging + + + + + + + +
+
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ + +
+

TNM Staging

+ + + + + +
+
+
Current TNM Stage
+
+
+
+
+
II
+
Stage Group
+
+
+
+
+
+
T
+
+
T2
+ Primary Tumor +
+
+
+
+
+
N
+
+
N0
+ Regional Nodes +
+
+
+
+
+
M
+
+
M0
+ Metastasis +
+
+
+
+
+ +
+ Last Updated +
March 15, 2025
+
+
+ By Dr. Smith +
+
+
+
+
+
+ + +
+ +
+
+
+
+
T
+
Primary Tumor
+
+
+
+
+
Current Classification
+ T2 +
+

Tumor > 2 cm but ≤ 5 cm in greatest dimension

+
+ + Tumor Size: 3.4 cm +
+
+ + Location: Left Upper Lobe +
+
+
+ +
+
+
+ + +
+
+
+
+
N
+
Regional Nodes
+
+
+
+
+
Current Classification
+ N0 +
+

No regional lymph node metastasis

+
+ + Nodes Examined: 12 +
+
+ + Nodes Positive: 0 +
+
+
+ +
+
+
+ + +
+
+
+
+
M
+
Distant Metastasis
+
+
+
+
+
Current Classification
+ M0 +
+

No distant metastasis

+
+ + Method: CT Scan +
+
+ + Last Evaluated: March 12, 2025 +
+
+
+ +
+
+
+
+ + +
+
+
TNM Staging History
+
+
+
+
+
+ +
+
+
+
+
Initial Diagnosis
+ Stage II +
+
+ T2 + N0 + M0 +
+ March 15, 2025 +

Based on CT scan, PET scan, and biopsy results.

+
+
+
+ +
+
+ +
+
+
+
+
Initial Diagnosis
+ Stage II +
+
+ T2 + N0 + M0 +
+ February 28, 2025 +

Initial clinical staging based on imaging studies.

+
+
+
+
+
+
+ + +
+ +
+

+ +

+
+
+

The TNM staging system is an internationally recognized method used by healthcare professionals to classify the extent of cancer spread. It helps determine the most appropriate treatment and provides information about prognosis.

+
+
+
+
+
T Category
+

Describes the size and extent of the primary tumor.

+
    +
  • T0: No evidence of primary tumor
    • +
  • Tis: Carcinoma in situ
    • +
  • T1-T4: Increasing size and/or local extension
    • +
+
+
+
+
+
+
+
N Category
+

Describes whether the cancer has spread to nearby lymph nodes.

+
    +
  • N0: No regional lymph node involvement
    • +
  • N1-N3: Increasing involvement of regional lymph nodes
    • +
+
+
+
+
+
+
+
M Category
+

Describes whether the cancer has spread to distant parts of the body.

+
    +
  • M0: No distant metastasis
    • +
  • M1: Distant metastasis present
    • +
+
+
+
+
+
+
+
+ + +
+

+ +

+
+
+

The combination of T, N, and M categories determines the overall stage group, which is typically numbered from I (least advanced) to IV (most advanced).

+
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
StageTNM CriteriaDescription
Stage 0Tis, N0, M0Carcinoma in situ, no spread
Stage IT1, N0, M0Small tumor, no lymph node involvement, no metastasis
Stage IIT2, N0, M0Larger tumor, no lymph node involvement, no metastasis
Stage IIIAny T, N1-2, M0Any size tumor, regional lymph node involvement, no metastasis
Stage IVAny T, Any N, M1Any size tumor, any lymph node status, distant metastasis
+
+
+
+
+ + +
+

+ +

+
+
+
+
+
+
+
Clinical Staging (cTNM)
+
+
+

Based on physical examination, imaging studies, and biopsies performed before treatment begins.

+
    +
  • Helps determine initial treatment approach
    • +
  • May be less accurate than pathological staging
    • +
  • Uses prefix "c" (e.g., cT2N0M0)
    • +
+
+
+
+
+
+
+
Pathological Staging (pTNM)
+
+
+

Based on examination of tissue removed during surgery, providing more precise information.

+
    +
  • More accurate assessment of disease extent
    • +
  • May guide additional treatment decisions
    • +
  • Uses prefix "p" (e.g., pT2N0M0)
    • +
+
+
+
+
+
+
+
+
+
+
+
+ +
+ + + + + + + + + + + + + + + + \ No newline at end of file diff --git a/views/pages/patient/treatment-plans.html b/views/pages/patient/treatment-plans.html new file mode 100644 index 0000000..9a0d8ab --- /dev/null +++ b/views/pages/patient/treatment-plans.html @@ -0,0 +1,997 @@ + + + + + + MedConnect - Treatment Plans + + + + + + + +
+
+ +
+
+ +
+
John Doe
+ Patient +
+
+
+ + Dashboard + + + Cancer Conditions + + + Disease Status + + + Test Results + + + TNM Staging + + + Risk Assessments + + + Treatment Plans + + + Appointments + + + Reports + + + Profile + +
+
+ + +
+
+

Treatment Plans

+
+ + +
+
+ + +
+
+
+
Active Treatment Plan
+ Stage II Breast Cancer +
+
+
+
+
+

Primary Cancer: Breast Cancer (Left)

+

Diagnosis Date: January 15, 2025

+

TNM Stage: T2N1M0 (Stage IIB)

+

Histology: Invasive Ductal Carcinoma

+
+
+

Oncologist: Dr. Sarah Johnson

+

Protocol: AC-T (Adriamycin/Cyclophosphamide followed by Taxol)

+

Treatment Goal: Curative

+

Last Updated: March 18, 2025

+
+
+ +
+
Overall Progress
+
+
+
+
+ Started: Jan 25, 2025 + 4 of 8 cycles completed + Expected completion: Jul 25, 2025 +
+
+
+
+ + + + +
+ +
+
+
Phase 1: Surgery
+

Lumpectomy with Sentinel Lymph Node Biopsy

+ +
+
+
+
Pre-operative Assessment
+

Complete blood count, chest X-ray, ECG

+
+
Completed
+
+ January 20, 2025 +
+ +
+
+
+
Breast-conserving Surgery
+

Left breast lumpectomy with sentinel lymph node biopsy

+
+
Completed
+
+ January 25, 2025 +
+ +
+
+
+
Post-operative Follow-up
+

Wound assessment, pathology review

+
+
Completed
+
+ February 5, 2025 +
+
+ +
+
Phase 2: Chemotherapy
+

AC-T Protocol (Adriamycin/Cyclophosphamide followed by Taxol)

+ +
+
+
+
AC Cycle 1
+

Adriamycin 60mg/m² + Cyclophosphamide 600mg/m²

+
+
Completed
+
+ February 15, 2025 +
+ +
+
+
+
AC Cycle 2
+

Adriamycin 60mg/m² + Cyclophosphamide 600mg/m²

+
+
Completed
+
+ March 8, 2025 +
+ +
+
+
+
AC Cycle 3
+

Adriamycin 60mg/m² + Cyclophosphamide 600mg/m²

+
+
Completed
+
+ March 29, 2025 +
+ +
+
+
+
AC Cycle 4
+

Adriamycin 60mg/m² + Cyclophosphamide 600mg/m²

+
+
In Progress
+
+ April 19, 2025 +
+ +
+
+
+
Paclitaxel Cycle 1
+

Paclitaxel 80mg/m² weekly

+
+
Scheduled
+
+ May 10, 2025 +
+ +
+
+
+
Paclitaxel Cycle 2
+

Paclitaxel 80mg/m² weekly

+
+
Pending
+
+ May 17, 2025 +
+ +
+
+
+
Paclitaxel Cycle 3
+

Paclitaxel 80mg/m² weekly

+
+
Pending
+
+ May 24, 2025 +
+ +
+
+
+
Paclitaxel Cycle 4
+

Paclitaxel 80mg/m² weekly

+
+
Pending
+
+ May 31, 2025 +
+
+ +
+
Phase 3: Radiation Therapy
+

Whole Breast Irradiation

+ +
+
+
+
Radiation Planning
+

CT simulation for treatment planning

+
+
Pending
+
+ June 15, 2025 +
+ +
+
+
+
Whole Breast Radiation
+

15 fractions over 3 weeks

+
+
Pending
+
+ June 20 - July 10, 2025 +
+
+ +
+
Phase 4: Hormone Therapy
+

Endocrine Therapy (ER+/PR+ tumor)

+ +
+
+
+
Hormone Therapy Initiation
+

Tamoxifen 20mg daily

+
+
Pending
+
+ July 20, 2025 +
+ +
+
+
+
Long-term Hormone Therapy
+

Continuation for 5-10 years

+
+
Pending
+
+ July 2025 - July 2030 +
+
+
+ + +
+
Current Medications
+ +
+
+
+
Adriamycin (Doxorubicin)
+

Chemotherapy - Anthracycline

+

Chemotherapy

+
+
+

Dose: 60mg/m²

+

Frequency: Every 21 days

+

Remaining: 0 of 4 cycles

+
+
+
+ +
+
+
+
Cyclophosphamide
+

Chemotherapy - Alkylating agent

+

Chemotherapy

+
+
+

Dose: 600mg/m²

+

Frequency: Every 21 days

+

Remaining: 0 of 4 cycles

+
+
+
+ +
+
+
+
Ondansetron (Zofran)
+

Anti-nausea medication

+

Supportive Care

+
+
+

Dose: 8mg

+

Frequency: Every 8 hours as needed

+

Instructions: Take 30 minutes before chemotherapy and continue for 2-3 days after

+
+
+
+ +
+
+
+
Dexamethasone
+

Corticosteroid - Anti-inflammatory

+

Supportive Care

+
+
+

Dose: 12mg

+

Frequency: Once before each chemotherapy session

+

Instructions: Take 30-60 minutes before chemotherapy

+
+
+
+ +
+
+
+
Filgrastim (Neupogen)
+

Growth factor - Neutropenia prevention

+

Supportive Care

+
+
+

Dose: 300mcg

+

Frequency: Daily for 5 days after each chemotherapy cycle

+

Instructions: Subcutaneous injection, starting 24 hours after chemotherapy completion

+
+
+
+ +
Upcoming Medications
+ +
+
+
+
Paclitaxel (Taxol)
+

Chemotherapy - Taxane

+

Chemotherapy

+
+
+

Dose: 80mg/m²

+

Frequency: Weekly

+

Duration: 4 cycles

+
+
+
+ +
+
+
+
Tamoxifen
+

Hormone therapy - Selective estrogen receptor modulator (SERM)

+

Hormone Therapy

+
+
+

Dose: 20mg

+

Frequency: Daily

+

Duration: 5-10 years

+
+
+
+
+ + +
+
+
Current Management
+

The following side effects have been reported and are being actively managed:

+
+ +
+
+
Nausea and Vomiting
+ +
+
+

Severity: Moderate

+

Management:

+
    +
  • Ondansetron (Zofran) 8mg every 8 hours as needed
    • +
  • Dexamethasone 8mg before chemotherapy
    • +
  • Small, frequent meals throughout the day
    • +
  • Adequate hydration
    • +
  • Avoid strong smells and greasy foods
    • +
+

Status: Well-controlled with medications

+
+
+ +
+
+
Fatigue
+ +
+
+

Severity: Moderate

+

Management:

+
    +
  • Balanced rest and activity periods
    • +
  • Light physical activity as tolerated
    • +
  • Adequate hydration
    • +
  • Nutritional support
    • +
  • Energy conservation techniques
    • +
+

Status: Gradually improving between cycles

+
+
+ +
+
+
Hair Loss (Alopecia)
+ +
+
+

Severity: Severe

+

Management:

+
    +
  • Head covering options provided (wig, scarves, hats)
    • +
  • Scalp care education
    • +
  • Emotional support resources
    • +
+

Status: Expected to continue throughout treatment

+
+
+ +
+
+
Neutropenia
+ +
+
+

Severity: Moderate

+

Management:

+
    +
  • Filgrastim (Neupogen) prophylaxis
    • +
  • Infection prevention education
    • +
  • Weekly blood counts
    • +
  • Avoid crowds and sick contacts
    • +
+

Status: Well-managed with growth factors

+
+
+ + +
+ + +
+
+
Latest Clinical Notes
+
+ +
+
+
+
Oncology Visit - March 29, 2025
+ Dr. Sarah Johnson +
+
+
+

Assessment: Patient tolerated cycle 3 of AC with moderate nausea and fatigue. Blood counts have recovered appropriately. No evidence of disease progression. ECOG Performance Status 1.

+

Disease Status: Responding to treatment.

+

Labs: WBC 4.2, ANC 2.1, Hgb 11.2, Plt 150. Liver and kidney function tests within normal limits.

+

Plan:

+
    +
  • Proceed with cycle 4 of AC as scheduled on April 19
    • +
  • Continue with current supportive medications
    • +
  • Schedule echocardiogram prior to cycle 4 to assess cardiac function
    • +
  • Consider dose reduction of cycle 4 if neutropenia worsens
    • +
+
+
+ +
+
+
+
Oncology Visit - March 8, 2025
+ Dr. Sarah Johnson +
+
+
+

Assessment: Patient completed cycle 2 of AC with expected side effects. Grade 2 nausea, grade 1 fatigue, complete alopecia. No evidence of infection or other complications.

+

Disease Status: Clinical examination shows reduction in palpable disease.

+

Labs: WBC 3.8, ANC 1.9, Hgb 11.5, Plt 142. All other labs within normal limits.

+

Plan:

+
    +
  • Proceed with cycle 3 of AC as scheduled
    • +
  • Continue with current supportive medications
    • +
  • Consider adding Neulasta instead of Neupogen if neutropenia worsens
    • +
  • Patient educated on signs of febrile neutropenia and when to seek immediate medical attention
    • +
+
+
+ +
+
+
+
Surgical Oncology Follow-up - February 5, 2025
+ Dr. Michael Chen +
+
+
+

Assessment: Patient recovering well from left breast lumpectomy with sentinel lymph node biopsy. Incision healing appropriately with no signs of infection.

+

Pathology Results: Invasive ductal carcinoma, grade 2, 2.8cm. Margins negative. 1 of 3 sentinel lymph nodes positive for metastatic disease. ER/PR positive, HER2 negative.

+

TNM Stage: pT2N1M0, Stage IIB.

+

Plan:

+
    +
  • Refer to medical oncology for adjuvant chemotherapy
    • +
  • Recommend AC-T regimen based on tumor characteristics and nodal involvement
    • +
  • Follow-up in 3 months or after completion of chemotherapy
    • +
+
+
+
+
+ + +
+
+
+
+
Care Team
+
+
+
+
+
+ +
+
+
+
Dr. Sarah Johnson
+
Medical Oncologist
+
s.johnson@medconnect.org
+
(555) 123-4567
+
+
+ +
+
+
+ +
+
+
+
Dr. Michael Chen
+
Surgical Oncologist
+
m.chen@medconnect.org
+
(555) 123-4568
+
+
+ +
+
+
+ +
+
+
+
Emily Rodriguez, RN
+
Oncology Nurse Navigator
+
e.rodriguez@medconnect.org
+
(555) 123-4569
+
+
+
+
+
+ +
+
+
+
Resources & Support
+
+
+
+
Support Groups
+

Breast Cancer Support Network

+

Meets every Tuesday at 6:00 PM in the Cancer Center, Room 205

+
+ +
+
Educational Materials
+

Understanding Your Treatment: AC-T Chemotherapy

+

PDF guide available for download

+
+ +
+
Financial Assistance
+

Cancer Care Financial Support Program

+

Contact: Maria Lopez at (555) 123-4570

+
+ +
+
Wellness Programs
+

Oncology Nutrition Services

+

Call (555) 123-4571 to schedule a consultation

+
+
+
+ +
+
+
+
+
+
+
+ +
+ + + + + + \ No newline at end of file